Table 2.
Comparison of PFGE pattern with antimicrobial susceptibility, OXA genes and source (wards) of isolates (%).
| CloneAntibiotics, genes and wards | Clone A | Clone B | Clone C | Clone D | Clone E | Clone F | Clone G | Clone H | P-value |
|---|---|---|---|---|---|---|---|---|---|
| IPM | 32(91) | 20(69) | 17(89) | 7(70) | 3(75) | 3(100) | 1(33) | 0 | 0.030 |
| MEM | 31(88) | 19(65) | 13(68) | 8(80) | 2(50) | 3(100) | 2(66) | 0 | 0.146 |
| CRO | 32(91) | 27(93) | 18(94) | 10(100) | 3(75) | 3(100) | 1(33) | 1(100) | 0.027 |
| CPD | 35(100) | 29(100) | 19(100) | 9(90) | 2(50) | 3(100) | 2(66) | 1(100) | <0.001 |
| AMP | 35(100) | 29(100) | 18(94) | 9(90) | 2(50) | 3(100) | 3(100) | 1(100) | <0.001 |
| SXT | 20(57) | 15(51) | 14(73) | 2(20) | 3(75) | 1(33) | 3(100) | 0 | 0.079 |
| TGC | 1(2) | 0 | 0 | 2(20) | 0 | 0 | 0 | 0 | 0.094 |
| Carbapenemase | 34(98) | 22(76) | 17(89) | 7(70) | 4(100) | 3(100) | 2(66) | 0 | 0.02 |
| MBL | 30(85) | 22(75) | 16(84) | 7(70) | 3(75) | 3(100) | 2(66) | 1(100) | 0.854 |
| ESBL | 19(54) | 12(42) | 12(63) | 5(50) | 2(50) | 1(33) | 1(33) | 0 | 0.768 |
| MDR | 12(34) | 10(34) | 7(36) | 1(10) | 1(25) | 2(66) | 1(33) | 0 | 0.705 |
| PDR | 4(11) | 2(7) | 2(10) | 1(10) | 0 | 0 | 0 | 0 | 0.823 |
| Oxa23 | 28(80) | 23(79) | 16(84) | 7(70) | 1(25) | 3(100) | 3(100) | 0 | 0.081 |
| Oxa24 | 7(20) | 5(17) | 3(15) | 0 | 1(25) | 2(66) | 2(66) | 0 | 0.113 |
| Urgency | 6(17) | 2(7) | 3(15) | 1(10) | 1(25) | 1(33) | 1(33) | 1(100) | 0.198 |
| ICU | 21(60) | 24(82) | 15(79) | 8(80) | 3(75) | 2(66) | 2(66) | 0 | 0.198 |
| Children | 1(2.8) | 3(10) | 1(5.2) | 1(10) | 0 | 0 | 0 | 0 | 0.198 |
| Infection | 7(20) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.198 |
IPM: Imipenem, MEM: Meropenem, CRO: Ceftriaxone, CPD: Cephpodoxime, AMP: Ampicillin, SXT: trimethoprim/sulfamethoxazole, TGC: Tigecylcine, MBL:, ESBL: extended-spectrum-beta-lactamase, MDR: multidrug resistant, PDR: pandrug resistant, ICU: intensive care units, P marked in bold if <0.05.